EUMAR TECHNOLOGY LIMITED
Company number 01884830 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
🏥 Financial Health Assessment: Eumar Technology Limited
"Annual Check-up for Companies House Registration 01884830"
📋 Patient Profile
| Attribute | Detail |
|---|---|
| Patient ID | 01884830 |
| Age | 40 years (incorporated 1985) |
| Specialty | Clean room technology, medical device manufacturing |
| Ward | Whitestone Business Park, Hereford |
| Consultants | Acre Accountancy Limited |
| Filing Status | Unaudited abridged accounts, small companies regime |
1️⃣ Financial Health Score: A- (Excellent)
"A mature, financially robust patient with a strong balance sheet and a hearty pulse of profitability — though a couple of vital signs deserve monitoring."
Score Justification: - ✅ Decades of operational longevity (40+ years) - ✅ Strong profit generation - ✅ Excellent solvency and liquidity - ✅ Improving net worth trajectory - ⚠️ Minor attention needed on cash trend and receivables - ⚠️ Recent director turnover
2️⃣ Key Vital Signs — Critical Metrics
🩺 Pulse & Blood Pressure (Liquidity Ratios)
| Metric | 2025 | 2024 | Reading |
|---|---|---|---|
| Current Ratio | 8.42 | 4.43 | 🟢 Exceptional — vastly exceeds healthy benchmark of 1.5–2.0 |
| Quick Ratio (excl. stock) | 7.03 | 3.28 | 🟢 Very strong |
| Cash Ratio | 2.11 | 1.92 | 🟢 Bullish — could pay off all short-term debt twice over |
Interpretation: The "circulatory system" is in superb shape. The company has £2.11 in cash for every £1 of short-term obligation.
❤️ Heart Function (Profitability)
| Metric | 2025 | Note |
|---|---|---|
| Profit for Year | £624,570 | Robust — built from retained earnings movement |
| Dividends Paid | £1,100 | Conservative distribution, capital retained for reinvestment |
| Profit Margin Proxy (Net Assets growth) | +18.8% | Strong YoY equity growth |
🦴 Bone Density (Solvency)
| Metric | 2025 | Reading |
|---|---|---|
| Total Liabilities | £323,446 | 🟢 Very low — £732K reduction since 2022 |
| Debt-to-Equity | 0.082 (8.2%) | 🟢 Excellent — minimal leverage |
| Net Assets | £3,941,269 | 🟢 Substantial, growing 18.8% YoY |
| Provisions for Liabilities | £408,466 | Likely deferred tax — a "healthy" liability |
🩸 Blood Test (Working Capital & Asset Quality)
| Metric | 2025 | 2024 | YoY Change |
|---|---|---|---|
| Net Current Assets | £2,400,405 | £1,693,119 | +41.8% 🟢 |
| Stock | £452,042 | £566,080 | -20.1% 🟡 Watch |
| Debtors | £1,590,048 | £674,184 | +135.9% 🔴 Investigate |
| Cash | £681,761 | £946,562 | -28.0% 🔴 Notable |
| Tangible Fixed Assets | £1,955,502 | £2,050,005 | Slight reduction after £303K additions |
3️⃣ Diagnosis — What the Numbers Reveal
🟢 Positive Symptoms (Signs of Robust Health)
-
"Strong heart" — Profitable Operations: The retained earnings grew by £623,470 in 2025, indicating genuine operational profitability, not just balance sheet manipulation.
-
"Excellent immune system" — name shown to subscribers Debt Burden: With debt-to-equity at 8.2% and creditors falling due within one year at just £323K, the company is rarely vulnerable to creditor pressure.
-
"Good muscle tone" — Asset Base Strength: Net assets of £3.94M with £1.96M in productive tangible assets (leasehold property, plant, machinery) show real operational substance.
-
"Clean circulation" — Working Capital: The £2.4M working capital provides ample "blood flow" to fund day-to-day operations comfortably.
-
"Mature patient" — 40 Years of Continuous Trading: Few companies survive four decades. This longevity signals durable business model, market adaptation, and resilience.
🟡 Symptoms Requiring Monitoring
-
"Depleted cash reserves" — The £264K cash decline is the most concerning vital sign. While still healthy at £682K, the company is consuming cash faster than replenishing it from operations.
-
"Swelling receivables" — Debtors doubled to £1.59M. This is the single largest "yellow flag": - Could indicate strong sales (positive) - Could indicate collection difficulties (negative) - Action required: Analyse debtor aging and days sales outstanding
-
"Reduced inventory" — Stock fell 20% while debtors rose. This could indicate: - Faster inventory turnover (good) - Stock shortages from supply issues (bad) - Strategic reduction tied to lower demand
🔴 Items Worth a Closer Look
-
The 2020 Anomaly: Total assets jumped from £1.48M (2019) to £7.36M (2020) — a near-fivefold increase. This suggests a major acquisition, asset injection, or business combination. Understanding this is key to interpreting recent trends.
-
"Governance refresh" — Two director resignations in 2026 (name shown to subscribers, name shown to subscribers). May simply reflect normal board evolution, but warrants noting in governance review.
-
Complex share structure: Multiple share classes (F, R, S, M, E, ED) suggest historical succession planning among a family-connected ownership group.
Historical Patient Chart — The Recovery Story
Net Assets Trajectory (£M)
2016: 0.67 → 2017: 0.72 → 2018: 0.60 → 2019: 0.72
↓ Major event 2020
2020: 2.78 → 2021: 4.10 → 2022: 3.36 → 2023: 3.72
↓ Post-event adjustment & debt reduction
2024: 3.32 → 2025: 3.94 📈 Recovery & Growth
The 2020-2021 surge followed by 2022 dip is a classic "consolidation period" pattern. Since 2022, the patient has steadily improved.
4️⃣ Recommendations — Prescriptions for Continued Wellness
💊 Immediate Actions (Within 30 days)
-
Conduct a Debtor Audit: With debtors now at £1.59M (a £916K increase), implement a debtor aging analysis. Identify: - How much is over 60/90 days? - What's the credit control process? - Is bad debt provision appropriate?
-
Cash Flow Reconciliation: Investigate the £264K cash reduction. Was it: - Used to fund the £303K tangible asset additions? - Locked up in debtors? - Spent on something else?
🏃 Short-term Actions (1-3 months)
-
Strengthen Cash Reserves: Consider a working capital facility or improved collection cycle to rebuild cash buffer. Target: maintain cash above £1M for operational resilience.
-
Director Succession Plan: With two recent resignations, formalise succession procedures and ensure continuity, especially given the family-connected ownership structure.
-
Dividend Policy Review: With profits of £625K but only £1,100 in dividends, consider whether shareholders might benefit from modest distributions while maintaining reserves.
🛌 Long-term Wellness Plan (3-12 months)
-
Scenario Planning: Given the 2020 anomaly and post-pandemic operating environment, model scenarios for: - Continued growth trajectory - Economic downturn resilience - Major capital investment opportunities
-
Pension & Employee Retention: With 38 stable employees, ensure pension obligations and key-person risks are managed.
-
Industry-Specific Risk Management: For medical device manufacturing: - Regulatory compliance (MHRA, CE marking, potential EU MDR) - Quality assurance certifications (ISO 13485) - Supply chain resilience for medical-grade materials
🩺 Annual Check-up Frequency
The patient should be reviewed annually at minimum, with quarterly "blood pressure checks" on cash and receivables given current trends.
📊 Final Assessment Summary
| Category | Grade | Comments |
|---|---|---|
| Profitability | A | Consistent, strong profit generation |
| Liquidity | A+ | Industry-leading current ratio |
| Solvency | A | Minimal debt, strong equity base |
| Asset Quality | B+ | Receivables warrant monitoring |
| Cash Management | B | Trend declining — needs attention |
| Governance | B+ | Recent changes — watch for transition |
| Overall | A- | Financially very healthy |